BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35377951)

  • 1. A practical framework for the targeted use of total neoadjuvant therapy for rectal cancer.
    Bhutiani N; Peacock O; Chang GJ
    Cancer; 2022 Jun; 128(11):2064-2072. PubMed ID: 35377951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 3. [Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].
    Zhang YQ; Sun KG; Lu JY; Ma J; Yao N; Qin ZH; Yao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):531-538. PubMed ID: 35754218
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 5. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of locally advanced rectal cancer therapy and future prospects.
    Koukourakis IM; Kouloulias V; Tiniakos D; Georgakopoulos I; Zygogianni A
    Crit Rev Oncol Hematol; 2023 Jun; 186():103992. PubMed ID: 37059276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
    Cercek A; Roxburgh CSD; Strombom P; Smith JJ; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Seier K; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Crane CH; Gollub MJ; Garcia-Aguilar J; Saltz LB; Weiser MR
    JAMA Oncol; 2018 Jun; 4(6):e180071. PubMed ID: 29566109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview.
    Guida AM; Sensi B; Formica V; D'Angelillo RM; Roselli M; Del Vecchio Blanco G; Rossi P; Capolupo GT; Caricato M; Sica GS
    Biol Direct; 2022 Jun; 17(1):16. PubMed ID: 35698084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total neoadjuvant therapy for rectal cancer: An emerging option.
    Ludmir EB; Palta M; Willett CG; Czito BG
    Cancer; 2017 May; 123(9):1497-1506. PubMed ID: 28295220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified Total Neoadjuvant Therapy
    DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
    Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
    Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Total Neoadjuvant Therapy Followed by Radical Resection Versus Conventional Therapy for Locally Advanced Rectal Cancer.
    Wright ME; Beaty JS; Thorson AG; Rojas R; Ternent CA
    Dis Colon Rectum; 2019 May; 62(5):568-578. PubMed ID: 30964794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving role of neoadjuvant therapy in rectal cancer.
    Schrag D
    Curr Treat Options Oncol; 2013 Sep; 14(3):350-64. PubMed ID: 23828092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
    Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G
    Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total neoadjuvant therapy for rectal cancer: a guide for surgeons.
    Johnson GGRJ; Park J; Helewa RM; Goldenberg BA; Nashed M; Hyun E
    Can J Surg; 2023; 66(2):E196-E201. PubMed ID: 37085291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
    Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
    BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.